The Platelet Inhibitory Effects and Pharmacokinetics of Prasugrel After Administration of Loading and Maintenance Doses in Healthy Subjects
Joseph A. Jakubowski(Indiana Biosciences Research Institute), Kenneth J. Winters(Eli Lilly (United States)), Christopher D. Payne(Eli Lilly (United States)), Nagy A. Farid(Eli Lilly (United States)), Govinda Weerakkody(Eli Lilly (United States)), John T. Brandt(Universitätsklinikum Würzburg), Grace Ying Li(Eli Lilly (United States)), David S. Small(Eli Lilly (United States)), Hideo Naganuma(Daiichi-Sankyo (Japan))
Cited by 89
Related Papers
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents
|Journal of the American College of Cardiology|2012|617